消息面上，据央广网消息，当前正值流感等呼吸道传染病高发季节，奥司他韦、玛巴洛沙韦等流感药物 的需求量不断增加。数据显示，奥司他韦近七天销量增长率达237%，玛巴洛沙韦上涨达180%。公开资 料显示，东阳光药有着"流感药物之王"称号，旗下的流感药物奥司他韦（商品名：可威）长期占据着国 内主要市场份额。 智通财经APP获悉，东阳光药(06887)早盘涨超4%，截至发稿，涨3.43%，报45.88港元，成交额454.31万 港元。 此外，11月25日晚，东阳光药发布公告称，公司有意于公开市场上购回自身股份。公司管理层对集团前 景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为建 议回购符合公司与公司股东的整体最佳利益。 ...

Group 1 - Dongyangguang executed a block trade on November 25, with a transaction volume of 2.8976 million shares and a transaction amount of 55.9237 million yuan, at a price of 19.30 yuan, which represents an 11.87% discount compared to the closing price of the day [2] - The buyer of the block trade was Zhongyou Securities Co., Ltd. Beijing Branch, while the seller was China Galaxy Securities Co., Ltd. Hangzhou Tiancheng East Road Securities Branch [2] - In the last three months, Dongyangguang has recorded a total of 5 block trades, with a cumulative transaction amount of 119 million yuan [2] Group 2 - On the same day, Dongyangguang's closing price was 21.90 yuan, reflecting a 5.80% increase, with a turnover rate of 1.99% and a total transaction amount of 1.296 billion yuan [2] - The net inflow of main funds for the day was 175 million yuan, and over the past five days, the stock has increased by 3.79%, with a total net inflow of 94.8392 million yuan [2] - The latest margin financing balance for Dongyangguang is 2.713 billion yuan, with a recent increase of 506,200 yuan, representing a growth rate of 0.02% [2]

（编辑 姚尧） 证券日报网讯 11月25日晚间，东阳光发布公告称，广东东阳光科技控股股份有限公司（以下简称"公 司"）于2025年11月25日召开公司2025年第二次职工代表大会，选举张光芒先生为公司第十二届董事会 职工代表董事。 ...

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) intends to repurchase its own shares in the open market, reflecting the management's confidence in the company's long-term business prospects and development [1] Group 1 - The management team believes that the share repurchase proposal is in the best interest of both the company and its shareholders [1]

东阳光（600673）药(06887)发布公告，公司有意于公开市场上购回自身股份。公司管理层对集团前景 充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为建议 回购符合公司与公司股东的整体最佳利益。 ...

格隆汇11月25日丨东阳光药(06887.HK)公告，公司有意于公开市场上购回自身股份。公司管理层对集团 前景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为 建议回购符合公司与公司股东整体最佳利益。 ...

Core Insights - The "2025 CDCC SUMMIT China Data Center Standard Conference" featured a forum focused on the collaboration between computing power and product innovation, emphasizing the challenges and advancements in the AI-driven power system and computing architecture [1] Group 1: Event Overview - The forum was co-hosted by CDCC and Beijing Qinhuai Data Co., Ltd, gathering representatives from cloud vendors, energy storage, and equipment suppliers to discuss the future of computing power centers [1] - The theme of the forum was "Condensing Product Efficiency = Opening New Chapters in Computing Power" [1] Group 2: Solutions and Innovations - Qinhuai Data, in collaboration with partners, launched the "Full-Stack Solution for Computing Power Centers NEXT," which optimizes key systems such as power access, supply and distribution, cooling, and operation and maintenance for large-scale AI computing centers [1][2] - The solution aims to address challenges such as increased resource demand and load fluctuations in the AI era by enhancing energy supply, architecture design, and product innovation [1] Group 3: Resource and System Architecture - The solution focuses on building self-sufficient capabilities for high-density AI computing factories through green power, IT-level energy storage solutions, and wastewater recycling, reducing external dependencies [2] - It includes upgrades in building design, power supply, and cooling processes, emphasizing modular, standardized, and prefabricated product development for operational and cost efficiency [2] Group 4: Recognition and Awards - Qinhuai Data's innovative practices were recognized at the conference, with its "Efficient Low-Carbon Ultra-Large Scale Liquid Cooling Commercial Data Center Project" winning the "2025 TOP 10 Excellent Data Center Case" award, highlighting its focus on safety, reliability, energy efficiency, and sustainability [2]

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 | 号 2025-68 | | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | | 张光芒先生符合《公司法》等相关法律法规及《公司章程》中关于职工代表 董事任职的资格和条件。本次选举后，公司第十二届董事会仍由 9 位董事组成， 其中兼任公司高级管理人员职务的董事以及由职工代表担任的董事人数总计未 超过公司董事总数的二分之一，符合相关法律法规及《公司章程》的规定。 特此公告。 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 章程指引》及《公司章程》的有关规定，广东东阳光科技控股股份有限公司（以 下简称"公司"）于 2025 年 11 月 25 日召开公司 2025 年第二次职工代表大会， 选举张光芒先生为公司第十二届董事会职工代表董事（简历详见附件），任期与 公司第十二届董事会董事一致 ...

Market Performance - The comprehensive sector increased by 2.55% compared to the previous trading day, with Dongyangguang leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up by 0.87%, while the Shenzhen Component Index closed at 12777.31, up by 1.53% [1] Stock Performance - Dongyangguang (600673) closed at 21.90, rising by 5.80% with a trading volume of 596,700 shares and a transaction value of 1.296 billion [1] - Other notable stocks include Zhangzhou Development (000753) at 8.13, up by 2.78%, and Nanjing Public Utilities (000421) at 7.14, up by 2.15% [1] Capital Flow - The comprehensive sector saw a net inflow of 48.78 million in main funds, while retail funds experienced a net outflow of 36.89 million [2] - The main funds for Dongyangguang had a net inflow of 172 million, representing 13.28% of its trading volume [3] Individual Stock Capital Flow - Dongyangguang had a significant net outflow from retail investors amounting to 90.89 million, indicating a divergence in investor sentiment [3] - Other stocks like Yatai Group (600881) and Nanjing Public Utilities (000421) also experienced mixed capital flows, with Yatai Group seeing a net inflow of 8.35 million from main funds [3]

Group 1 - The demand for flu-related medications is rising significantly as the flu season approaches, with several stocks in the sector experiencing price surges [1] - Notable stocks that have reached their daily limit include Jindike, Peking University Medicine, and Te Yi Pharmaceutical, among others [1] - Data from Alibaba Health indicates a more than 500% week-on-week increase in the number of people purchasing antiviral flu medications, with Mabalosavir showing a remarkable over 600% increase [1] Group 2 - Experts warn that the H3N2 strain circulating this year is different from previous years, leading to lower immunity in the population and increased transmission risk [2] - The flu virus is known to undergo antigenic drift, but current strains are still within seasonal levels and do not indicate a stronger evolution of the virus [2] Group 3 - Companies are actively ensuring the supply of flu medications and vaccines in response to rising demand [3] - Dongyang Sunshine, a major supplier of Oseltamivir, reports comprehensive coverage of its products across hospitals, pharmacies, and online platforms, maintaining sufficient inventory [3] - Hualan Biological has noted a significant increase in demand for flu vaccines since October, with plans to enhance market supply and ensure timely delivery through cold chain logistics [3]